Dr. Curtiland Deville Jr., MD

Dr. Deville practices at Sibley Memorial Hospital in Washington, District of Columbia, part of Johns Hopkins Health System.

Dr. Deville's NPI, 1700942562, was assigned on December 28, 2006. Dr. Deville graduated from The Warren Alpert Medical School of Brown University in 2005. Dr. Deville holds Pennsylvania license MD432945.

Dr. Deville's primary practice is Sibley Memorial Hospital, at 5255 Loughboro Rd NW, Washington, DC 20016 in The District County. The practice phone is (202) 537-4680.

Dr. Deville's primary practice is Sibley Memorial Hospital in Washington, District of Columbia, part of Johns Hopkins Health System. Dr. Deville is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Deville to 2 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Deville practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Deville's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Deville is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Deville's licenses on file in 6 states: Pennsylvania, Florida, District of Columbia, Maryland, Virginia and New Jersey.

Dmand AI lists bone cancer radiation and prostate cancer radiation among the conditions Dr. Deville treats.

CMS data shows 2,483 Medicare services from Dr. Deville across 11 procedure codes in 2024, for 200 Medicare patients. Medicare paid $166,175 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 200 Medicare patients who saw Dr. Deville in 2024. The largest group is 75 to 84, with 95 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.33, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Deville's median patient age at 76, with 5% women.

In 2024, Dr. Deville wrote 87 Medicare Part D claims for 44 patients. 72% of them were for generic drugs. CMS names the drug for 58 of them, across 2 drugs with 11 or more claims each, at $54,161 in total drug cost. In 2023, CMS named 52 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Deville for performance year 2024, reported as part of a group. CMS lists Dr. Deville as offering telehealth.

Dmand AI links 108 papers to Dr. Deville, published from 2011 to 2025. 2020 was the busiest year, with 15. The most frequent topics are Prostatic Neoplasms, Radiation Oncology and Workforce. Dr. Deville has published most often in Int J Radiat Oncol Biol Phys. Dr. Deville's most frequent co-authors are Phuoc T. Tran, MD, PhD, Theodore Leslie Deweese, MD and Awad Ahmed, MD.

Dmand AI links Dr. Deville to 4 clinical trials. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Sarcoma. Abramson Cancer Center at Penn Medicine sponsors the most, 3.

CMS Open Payments shows 3 general payments to Dr. Deville from 3 drug and device companies from 2016 to 2021. Consulting fees make up the largest share, 96% of the total. AstraZeneca Pharmaceuticals LP paid the most, $3,020.

Dmand AI lists 1 award for Dr. Deville, most recently CMS Stage 1 EHR in 2013.

Dr. Deville graduated from The Warren Alpert Medical School of Brown University in 2005. Dr. Deville is a member of AACR, ACR, ASTRO, ASCO, NMA and RSNA.

Dr. Deville is in network with 12 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.